Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma

Expert Opin Investig Drugs. 2009 Oct;18(10):1549-57. doi: 10.1517/13543780903183528.


Background: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas.

Objective: This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase.

Methods: We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas.

Results/conclusion: Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Glioblastoma / blood supply
  • Glioblastoma / drug therapy*
  • Humans
  • Quinazolines / adverse effects
  • Quinazolines / pharmacology*
  • Quinazolines / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Quinazolines
  • Receptors, Vascular Endothelial Growth Factor
  • cediranib